Researchers Design New Multi-Epitope Monkeypox Vaccine
A new vaccine candidate shows high global coverage potential after an analysis of 27 monkeypox virus genomes.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Do you trust that computational modeling effectively speeds up the creation of reliable, safe vaccines?
Scientists have developed a multi-epitope vaccine candidate designed to offer broader protection against the monkeypox virus than existing smallpox-derived options. The candidate, known as vaccine construct 2, was created using a conservation-guided immunoinformatics approach.
Why it matters
Current smallpox vaccines offer only partial protection, creating a need for more targeted solutions. This new approach aims to address that gap by focusing on highly conserved viral genes to ensure widespread effectiveness.
The vaccine candidate demonstrated binding affinities of -19.6 kcal/mol with TLR2 and -27.8 kcal/mol with TLR4-MD-2 receptors. This construct was selected from three designs based on its potential to induce interferon-gamma and antibody production.
The details
The research team utilized 27 complete monkeypox virus genomes to identify targets, applying codon optimization to allow for efficient expression in Escherichia coli. Molecular simulations indicate that the vaccine candidate, particularly construct 2, effectively engages key receptors involved in the human immune response.
Timeline
2001-2025: Period covered by the 27 analyzed monkeypox virus genomes.
Health Landscape
The study marks a departure from the reliance on the JYNNEOS smallpox and monkeypox vaccine, which is a legacy treatment currently used to address outbreaks. By shifting toward multi-epitope designs, researchers are moving away from traditional orthopoxvirus vaccine models.
This development represents a theoretical advancement that may eventually lead to more effective preventative options for the general public. It does not currently change existing vaccination protocols or the availability of treatments for patients.
The takeaway
While this vaccine candidate shows promise in simulations, it remains in the early stages of research. Developing and testing new medical interventions is a long process that requires rigorous scientific validation before clinical use.
Further reading
For more information on the evolving approach to viral outbreaks, visit our Diseases — General section.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that computational modeling effectively speeds up the creation of reliable, safe vaccines?
